{"id":"jecevax","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"JECEVAX contains a weakened form of Japanese encephalitis virus that triggers both humoral and cellular immune responses without causing disease. The vaccine primes the immune system to recognize and neutralize the virus upon natural exposure, providing protection against Japanese encephalitis infection.","oneSentence":"JECEVAX is a live attenuated Japanese encephalitis vaccine that stimulates immune responses against Japanese encephalitis virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:35.051Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Japanese encephalitis in endemic regions"}]},"trialDetails":[{"nctId":"NCT03204227","phase":"PHASE2","title":"Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age","status":"COMPLETED","sponsor":"National Institute of Hygiene and Epidemiology, Vietnam","startDate":"2017-06-02","conditions":"Japanese Encephalitis","enrollment":220},{"nctId":"NCT03282370","phase":"PHASE3","title":"Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam","status":"COMPLETED","sponsor":"National Institute of Hygiene and Epidemiology, Vietnam","startDate":"2017-09-30","conditions":"Japanese Encephalitis","enrollment":655},{"nctId":"NCT02816554","phase":"PHASE2","title":"Safety and Immunogenicity of JECEVAX in Young Children","status":"COMPLETED","sponsor":"National Institute of Hygiene and Epidemiology, Vietnam","startDate":"2015-04","conditions":"Japanese Encephalitis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JECEVAX","genericName":"JECEVAX","companyName":"National Institute of Hygiene and Epidemiology, Vietnam","companyId":"national-institute-of-hygiene-and-epidemiology-vietnam","modality":"Biologic","firstApprovalDate":"","aiSummary":"JECEVAX is a live attenuated Japanese encephalitis vaccine that stimulates immune responses against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in endemic regions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}